Research Advances for Virus-vectored Tuberculosis Vaccines and Latest Findings on Tuberculosis Vaccine Development
Tuberculosis (TB), caused by respiratory infection with Mycobacterium tuberculosis, remains a major global health threat. The only licensed TB vaccine, the one-hundred-year-old Bacille Calmette-Guérin has variable efficacy and often provides poor protection against adult pulmonary TB, the transmissi...
Main Authors: | Zhidong Hu, Shui-Hua Lu, Douglas B. Lowrie, Xiao-Yong Fan |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-06-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.895020/full |
Similar Items
-
Chimpanzee adenoviral vectors as vaccines – challenges to move the technology into the fast lane
by: Alessandra Vitelli, et al.
Published: (2017-12-01) -
Recombinant Pichinde viral vector expressing tuberculosis antigens elicits strong T cell responses and protection in mice
by: Natalie M. Kirk, et al.
Published: (2023-02-01) -
Tuberculosis vaccines update: Is an RNA-based vaccine feasible for tuberculosis?
by: Sasha E. Larsen, et al.
Published: (2023-05-01) -
Preclinical Evaluation of TB/FLU-04L—An Intranasal Influenza Vector-Based Boost Vaccine against Tuberculosis
by: Anna-Polina Shurygina, et al.
Published: (2023-04-01) -
Tuberculosis vaccine research in China
by: Douglas B Lowrie
Published: (2012-07-01)